DME

Oxular began a phase 2 trial for its therapeutic candidate OXU-001, for the treatment of diabetic macular edema in October 2024.

Investigators conducted a meta-analysis of randomized controlled trials to assess the efficacy and safety of brolucizumab compared with aflibercept in patients with DME.

Enhancing durability and reducing treatment burden.

Researchers conducted a retrospective study to assess serum inflammatory biomarkers in patients with different subtypes of diabetic macular edema (DME).

Early results suggest participant diversity and novel measures will enable new, artificial intelligence-driven insights. As the study evolves, it could lead to significant advancements in understanding how environmental exposures contribute not only to diabetes but also to its complications, including those affecting eye health, such as diabetic retinopathy.

The biosimilar now known by the brand name OPUVIZ was previously known as the biosimilar candidate SB15.

To educate the public—including parents, caregivers, and allied health professionals—Prevent Blindness is offering free educational resources, including fact sheets, social media graphics, web pages, and educational videos in both English and Spanish.

The Gr8 Eye Movement campaign by Prevent Blindness and Regeneron emphasizes the critical role of caregivers in eye health, revealing significant gaps in caregivers' awareness of retinal diseases and aging-related vision loss.

According to the company, Duravyu 2.7 mg demonstrated an early and sustained anatomical improvement mirroring BCVA results with a 68 micron reduction in CST. Full topline data is anticipated in Q1 of 2025.

Ophthalmologists discuss advancing treatment strategies to improve outcomes.

According to data presented in a late-breaking oral presentation at the American Academy of Ophthalmology 2024 Annual Meeting in Chicago.1 efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies.

A large study performed in Canada analyzed data and found that patients are at higher risk of multiple possible complications after cataract surgery.

David Eichenbaum, MD and Riad Sherif, MD, CEO of Oculis will present the updates with additional info on topline results from the ACUITY Phase 2 trial of OCS-05 for the treatment of acute optic neuritis (AON).

The event will focus on UNITY’s ongoing Phase 2b ASPIRE study, which is evaluating foselutoclax (UBX1325) head-to-head against aflibercept in DME.

Meeting in Stockholm provides education, updates, and a taste of culture.

MK-3000, formally known as EYE103, is an investigational, potentially first-in-class tetravalent, tri-specific antibody that acts as an agonist of the Wnt signaling pathway.

A team of researchers from Johns Hopkins Medicine and the University of Wisconsin-Madison conducted a study on the application of autonomous artificial intelligence and testing for diabetic eye disease.

The Phase 1 trial is a multicenter, open-label, dose-escalation safety clinical trial, with 18 subjects, who each have received a single periocular injection of AIV007

Investigators at the Faculty of Medicine at the University of Augsburg in Germany , found that in the eye of the mouse macrophages are already forming in the vitreous body in the embryonic stage.

EC-104 is a novel intravitreal (IVT) corticosteroid implant with intended 6 months durable drug release for the treatment of DME.

Michael Abramoff, MD, PhD, a retina specialist and founder and executive chairman of Digital Diagnostics, points out that much evidence has been collected over the past few decades showing that early detection is key.

In a study, a team of researchers with the OhioHealth Grant Medical Center Family Medicine practice implemented diabetic retinopathy screening using in-clinic retinal photographs and automated software analysis to increase screening rates.

The results from the trial in China met both the primary and secondary endpoints with no serious adverse events or new safety signals.

AG-73305 is bi-specific, with anti-VEGF and anti-integrin. The dual mechanism of action has provided some interesting results.

EyeBio is developing a pipeline of clinical and preclinical candidates for the prevention and treatment of vision loss associated with retinal vascular leakage.

According to Genentech, faricimab-svoa is the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that can cause blindness.

The biosimilar was approved for treating patients with age-related neovascular (wet) macular degeneration (nAMD) and other serious retinal diseases.